Greenland Mines Ltd

Greenland Mines Ltd, founded in 2004 and headquartered in Omaha, Nebraska, operates as a diversified company with interests in both natural resources and cell and gene therapy. The company's core mission involves unlocking the potential of the Skaergaard Intrusion for critical minerals and developing innovative therapies for neurodegenerative diseases.

In its natural resources division, Greenland Mines Ltd is focused on the exploration and development of the Skaergaard Project in Southeast Greenland. This project is recognized as one of the world's largest undeveloped deposits of palladium, gold, and platinum, with an estimated in-situ resource value of approximately $68 billion at February 2026 metal prices. The company also aims to expand its raw critical metals portfolio to include vanadium and gallium. Concurrently, its cell and gene therapy division is dedicated to developing treatments for neurodegenerative disorders such as Alzheimer's, amyotrophic lateral sclerosis (ALS), and Parkinson's, with a specific focus on its KLTO-202 program for ALS.

Greenland Mines Ltd, which rebranded from Klotho Neurosciences, Inc. in March 2026, is publicly traded on NASDAQ under the ticker GRML. Dr. Joseph Sinkule serves as the Founder, CEO, and Chairman of the Board, while Bo Møller Stensgaard is President, overseeing the natural resources segment. Recent developments include securing an additional 180-day period for Nasdaq bid price compliance, engaging WSP Denmark for an Environmental Impact Assessment (EIA) at Skaergaard, and signing a Letter of Intent for an Icelandic industrial processing site, underscoring its strategic positioning in the critical minerals supply chain.

Klotho Neurosciences, Inc. was a biogenetics and biotechnology company headquartered in Omaha, Nebraska, focused on the development of innovative, disease-modifying cell and gene therapies. Its mission centered on translating scientific discoveries related to the "anti-aging" human Klotho gene (s-KL) into therapies to combat age-related decline and neurodegenerative disorders. The company's pipeline included gene therapy candidates such as KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS and other motor neuron diseases, and KLTO-303 for broader age-related pathologies. Klotho Neurosciences also developed genomics-based diagnostic assays, including a "Klotho Clock" for biological aging. Additionally, the company held a generic drug portfolio, a biosimilar biologics platform for cancer treatment, and a treatment for small drug molecules affecting skin pigmentation, acquired from its predecessor entities. Led by CEO Dr. Joseph Sinkule, Klotho Neurosciences, Inc. was publicly traded on NASDAQ under the ticker KLTO. In November 2025, the company received the BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award. In early 2026, it announced positive preclinical results for its anti-aging gene therapy, demonstrating extended lifespan in mice. However, effective March 12, 2026, Klotho Neurosciences, Inc. rebranded to Greenland Mines Ltd and changed its Nasdaq ticker symbol to GRML, following its acquisition of Greenland Mines Corp. This strategic shift expanded the company's focus beyond biogenetics to include critical minerals development in Greenland.